LOC387715/HTRA1 and the Combined Photodynamic Therapy With Intravitreal Bevacizumab in Polypoidal Choroidal Vasculopathy

NCT01233115 | Completed DMC

• 1 other identifier: LOC387715/HTRA1 & combined PDT
• Study Type: observational
• Target: 70
• Locations: 1 country
• Sites: 1

Brief Summary

This study is to investigate whether there is an association of the LOC387715/HTRA1 variants with response to treatment with combined photodynamic therapy and intravitreal bevacizumab for patients with polypoidal choroidal vasculopathy.

Conditions

Age-Related Macular Degeneration

Outcome Measures

Primary Outcomes (1)

• Best-corrected visual acuity

  Best-corrected visual acuity (BCVA) using the Snellen chart was evaluated including BCVA up to 12 months

  up to 12 months

Secondary Outcomes (1)

• Angiographic characteristics

  up to 12 months

Study Arms (1)

polypoidal choroidal vasculopathy

patients who were treated for polypoidal choroidal vasculopathy with combined photodynamic therapy and intravitreal bevacizumab injections

Eligibility Criteria

• Age: 60 Years - 80 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

The authors did a retrospective chart review of 70 patients with PCV who were treated at the Department of Ophthalmology, Kyungpook National University Hospital in Daegu, Korea.

You may qualify if:

• patients older than 60 years of age at onset
• polyp-like terminal aneurysmal dilations with or without branching vascular networks in indocyanine green angiography (ICGA) and subretinal reddish-orange protrusions corresponding to polyp-like lesions
• patients who had combined photodynamic therapy and intravitreal bevacizumab injections, and followed up for more than 12 months after the first treatment

You may not qualify if:

• patients with retinal or choroidal diseases including pathologic myopia, angioid streaks, idiopathic choroidal neovascularization (CNV), presumed ocular histoplasmosis, and other secondary CNV
• patients who refused genotypic analyses

Sponsors & Collaborators

• Kyungpook National University Hospital: lead

Study Sites (1)

In Taek Kim

Daegu, Kyungsangpookdo, 700-721, South Korea

Location

Related Publications (1)

• Sakurada Y, Kubota T, Imasawa M, Mabuchi F, Tanabe N, Iijima H. Association of LOC387715 A69S genotype with visual prognosis after photodynamic therapy for polypoidal choroidal vasculopathy. Retina. 2010 Nov-Dec;30(10):1616-21. doi: 10.1097/IAE.0b013e3181e587e3.

  PMID: 20671585 RESULT

Related Links

• genetics home reference

Biospecimen

Retention: SAMPLES WITH DNA

Genomic DNA was extracted from peripheral blood. The two SNPs (rs10490924 in the LOC387715 locus and rs11200638 in HTRA1 gene) were analyzed by LC480 Real time PCR (Roche, Basel, Switzerland) at D\&P Biotech (Daegu, Korea).

MeSH Terms

Conditions

Macular Degeneration

Condition Hierarchy (Ancestors)

Retinal Degeneration; Retinal Diseases; Eye Diseases

Study Officials

• In Taek Kim, M.D.

  Kyungpook National University Hospital

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: RETROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: clinical professor

Study Record Dates

• First Submitted: November 1, 2010
• First Posted: November 3, 2010
• Study Start: October 1, 2010
• Primary Completion: August 1, 2011
• Study Completion: August 1, 2011
• Last Updated: August 30, 2011

Record last verified: 2011-08

Locations

KR (1)